Amorphous Sodium Salt TMC435 HCV Inhibitor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current HCV treatments with Pegylated interferon-alpha and ribavirin are poorly tolerated, have significant side effects, and are lengthy, with TMC435, a macrocyclic NS3 serine protease inhibitor, being poorly water-soluble, which limits its bioavailability and stability in crystalline form, making it difficult to develop effective and stable dosage forms.
Innovation Solution
Converting TMC435 into its stable amorphous sodium salt form through a spray-drying process, which improves bioavailability and stability, allowing for the creation of compact and easily manufactured pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If TMC435 is administered in crystalline form, then stability is improved, but bioavailability decreases
Solution Approach 1:
The patent converts the crystalline form of TMC435 to an amorphous form by changing the physical state parameter. This parameter change from crystalline to amorphous state improves bioavailability while maintaining stability through specific formulation approaches.
Solution Approach 2:
The patent creates a multi-functional solution where the amorphous form serves both stability and bioavailability requirements. The amorphous sodium salt formulation provides enhanced dissolution and absorption while maintaining shelf stability through proper formulation and storage conditions.
2Reliability
If higher doses of poorly soluble drugs are administered, then bioavailability problems are overcome, but dosage form size increases
Solution Approach 1:
The patent changes the physical state parameter from crystalline to amorphous, which dramatically improves dissolution rate and bioavailability. This allows lower doses to achieve therapeutic effect, resulting in smaller dosage form size while maintaining or improving bioavailability.
3Reliability
If the amorphous form is used, then bioavailability is improved, but stability decreases
Solution Approach 1:
The patent applies beforehand cushioning by using stabilizing excipients and formulation strategies that prevent or slow down the conversion of amorphous form to crystalline form. This cushioning approach maintains the amorphous state's bioavailability advantage while mitigating its inherent instability through protective formulation measures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The amorphous sodium salt of TMC435 is surprisingly stable, offering enhanced bioavailability and pharmacokinetic properties, enabling effective antiviral activity and stable storage, thus overcoming the limitations of crystalline forms in HCV treatment.
Implementation Method 1
conveniently be prepared by spray-drying as manufacturing procedure
Data Source
AI summary
The amorphous form of the sodium salt of the macrocyclic inhibitor of HCV of formula (I) as well as processes for manufacturing this salt.